Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective

William E Boden, Marcus D Flather, Deepak L Bhatt

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial has spurred debate over subgroup analysis interpretation and prompted renewed consideration of the long-term role of dual aspirin and clopidogrel therapy (DAPT) in patients with established vascular disease.
Original languageEnglish
Pages (from-to)207-16
Number of pages10
JournalCardiovascular Drugs and Therapy
Issue number3
Publication statusPublished - Jun 2010


  • Aspirin
  • Hemorrhage
  • Humans
  • Platelet Aggregation Inhibitors
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Risk
  • Thrombosis
  • Ticlopidine
  • Time Factors
  • Vascular Diseases

Cite this